| __timestamp | Bausch Health Companies Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 3401685 |
| Thursday, January 1, 2015 | 582800000 | 4284228 |
| Friday, January 1, 2016 | 455000000 | 3581295 |
| Sunday, January 1, 2017 | 366000000 | 4838300 |
| Monday, January 1, 2018 | 414000000 | 24891534 |
| Tuesday, January 1, 2019 | 471000000 | 31347891 |
| Wednesday, January 1, 2020 | 452000000 | 17480747 |
| Friday, January 1, 2021 | 465000000 | 34710152 |
| Saturday, January 1, 2022 | 529000000 | 108459978 |
| Sunday, January 1, 2023 | 604000000 | 181563523 |
| Monday, January 1, 2024 | 176326321 |
Infusing magic into the data realm
In the ever-evolving landscape of pharmaceuticals and biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Bausch Health Companies Inc. and Opthea Limited have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Bausch Health consistently allocated a significant portion of its resources to R&D, with expenditures peaking in 2023 at approximately 604 million USD. This represents a 145% increase from their 2014 spending. In contrast, Opthea Limited, while starting with a modest R&D budget, has shown a remarkable growth trajectory, with a staggering 5,236% increase in R&D spending over the same period, reaching around 182 million USD in 2023.
This data underscores the diverse strategies companies employ to prioritize innovation, with Opthea's aggressive growth in R&D spending highlighting its commitment to advancing its research capabilities.
Regeneron Pharmaceuticals, Inc. or Bausch Health Companies Inc.: Who Invests More in Innovation?
Research and Development Investment: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc.
Comparing Innovation Spending: Incyte Corporation and Opthea Limited
R&D Spending Showdown: Incyte Corporation vs Bausch Health Companies Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Opthea Limited
BioMarin Pharmaceutical Inc. vs Opthea Limited: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Analyzing R&D Budgets: Opthea Limited vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How Opthea Limited and Novavax, Inc. Allocate Funds
R&D Spending Showdown: Viking Therapeutics, Inc. vs Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Bausch Health Companies Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs Bausch Health Companies Inc.